report by BlackRock
Results for ""
Sustainable Investing
ESG in 2021: Closing the Expectations Gap
This piece is approved to use with clients.
Antony Marsden, Head of Governance and Responsible Investment, explores key themes related to Environmental, Social and Governance (ESG) investing in 2021, including why a rethink on ratings is necessary to align expectations with reality.
Sustainable Investing
Global Sustainable Equity: News and Opportunities
This piece is approved to use with clients.
Reflecting on the last quarter of 2020 and looking ahead to the opportunities in the world of sustainability.
Sustainable Investing
Think Sustainable
This investor guide answers four key questions to help get started with sustainable investing.
Client Experience
Which Advisors Had A Smoother Ride During COVID
Advisors should treat the pandemic as a turning point, making strategic changes to add the most value for what clients need today and do more with less.
Leveraging Technology & Data
Tech in Business
98% of advisors say that technology impacts their decision to join a new firm, with 70% saying it ‘significantly impacts’ that choice.
Client Experience
Enhance Client Relationships with Tech
The end of the year is an ideal time to check in with clients to gauge their financial and emotional wellbeing. Especially in the current environment, your clients may want reassurance that they’ll be okay.
Sustainable Investing
Influencing for good: 20 years of engagement
This piece is approved to use with clients.
The way investors conduct engagement has transformed. From a niche approach largely confined to mission-orientated investors, engagement is now a mainstream investor activity. The success of the Climate Action 100+ initiative in bringing together investors, representing close to US$40 trillion in assets, shows how far we have come.
Sustainable Investing
ESG Viewpoint – COVID-19 and the pharmaceutical industry
This piece is approved to use with clients.
Public trust in the pharmaceutical industry has eroded. The pandemic provides drug-makers a chance to begin re-building their reputation – but only if they prioritise socially responsible practices.